Identifying Good Candidates for Active Surveillance of Ductal Carcinoma <i>In Situ</i> : Insights from a Large Neoadjuvant Endocrine Therapy CohortAlexa Glencer, Laura J. Esserman|Cancer Research Communications|2022Cited by 13
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injectionAlexa Glencer, Michael J. Campbell, Nola M. Hylton et al.|npj Breast Cancer|2021Cited by 12